BCNP Consultants GmbH is an acknowledged consulting company specialized in the branches biotech, chemistry, nanotech and pharma (BCNP). Holger Bengs is its managing director. He founded the company in 2002 on the basis of nine years of professional experience in the chemical and pharmaceutical industry as well as in the capital market.
BCNP clients benefit from the very broad basis of natural scientific expertise of its consultants in the disciplines inorganic chemistry, biochemistry, biology, biotechnology, molecular biology, polymer chemistry and business chemistry. The team is completed by an experienced finance expert and a specialist for international marketing and branding.
BCNP consultants understand the technical, financial and market needs of their clients. The spectrum of clients ranges from university or research organisation based scientists, small and medium-sized corporations to big publicly traded companies as well as non-governmental organisations and foundations.
We advise and support foreign companies on their market entry in Germany, i.e. search for cooperation partners in industry and university, search for suitable sites, foundation of German subsidiaries, financing and funding, cultural coaching, and business development.
BCNP is very well connected to experts and decision makers in various industries. This is supported by manifold memberships, e.g. in BIO Deutschland, VBU (Association of German Biotechnology Companies), DECHEMA (German Society for Chemical Engineering and Biotechnology), EAPB (European Association of Public Banks), European Federation of Biotechnology (EFB), DV Nano (German Nanotechnology Association), ACS (American Chemical Society), RSC (Royal Society of Chemistry), Gesellschaft Deutscher Chemiker (German Chemical Society, GDCh), Gesundheitswirtschaft Rhein-Main, biosaxony, CLIB2021 and the Swiss-German Business Club.
Since 2007, BCNP has been advising the capital market specialist GoingPublic Media AG on the scientific issues biotechnology, industrial biotechnology and personalised medicine published as special editions of Germany´s GoingPublic and Venture Capital Magazine.
Since 2010, BCNP has been authorized by the Federal Ministry of Economics and Technology (BMWi) in the program BMWi-Innovationsgutscheine (go-Inno) and can help German companies in implementing innovative technologies (funding rate of 50 %).
Since 2013, BCNP has been contributing in the project “Bringing innovative industrial biotechnology research to the market” (IB2Market, 7th European Union's Research Framework Programme). BCNP is part of a multinational team (Belgium, Germany, England and Italy) and responsible for business cases and business plans.
BCNP Consultants GmbH
60486 Frankfurt am Main